Shares of Nyxoah S.A. (NASDAQ:NYXH – Get Rating) have been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $31.00.
Several analysts have recently issued reports on the stock. Wolfe Research began coverage on shares of Nyxoah in a research note on Tuesday, April 5th. They issued a “market perform” rating and a $21.00 target price for the company. Piper Sandler reduced their price target on shares of Nyxoah from $40.00 to $30.00 in a research report on Friday, March 25th. Finally, Oppenheimer began coverage on shares of Nyxoah in a research report on Wednesday, April 20th. They set an “outperform” rating and a $30.00 price target for the company.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NYXH. Credit Suisse AG purchased a new stake in Nyxoah during the third quarter valued at about $221,000. Allspring Global Investments Holdings LLC purchased a new stake in Nyxoah during the fourth quarter valued at about $2,895,000. Rossmore Private Capital lifted its holdings in Nyxoah by 29.7% during the fourth quarter. Rossmore Private Capital now owns 117,940 shares of the company’s stock valued at $2,494,000 after purchasing an additional 27,000 shares during the last quarter. Evolutionary Tree Capital Management LLC lifted its holdings in Nyxoah by 62.2% during the fourth quarter. Evolutionary Tree Capital Management LLC now owns 62,445 shares of the company’s stock valued at $1,436,000 after purchasing an additional 23,955 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in shares of Nyxoah by 51.4% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 455,262 shares of the company’s stock worth $10,471,000 after buying an additional 154,462 shares in the last quarter. 10.76% of the stock is currently owned by institutional investors and hedge funds.
Nyxoah Company Profile (Get Rating)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
- Get a free copy of the StockNews.com research report on Nyxoah (NYXH)
- Are These Cheap Copper Stocks Right For Your Portfolio?
- Zai Lab Stock Has Fallen to Value Levels
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.